Immatics (NASDAQ:IMTX) Bolsa

Immatics

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Immatics NV

The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations. 
What Happened:&nbsp;The Trump Administration is&nbsp;contemplating a policy to align U.S. drug prices with lower rates in other developed countries. The policy is likely to be enforced by the agency responsible for&nbsp;Medicare and Medicaid health programs, reported Reuters&nbsp;citing sources from the pharmaceutical industry.
The sources highlighted this policy as the pharmaceutical industry&#8217;s primary concern, surpassing other government actions under consideration, such as tariffs on imported medicines. One source labeled it as the most significant &#8220;existential&nbsp;threat to the industry and&nbsp;U.S. biosciences innovation.&#8221;
Though the Trump Administration hasn't directly addressed reference pricing, the conservative America First Policy Institute suggested it could be included in Medicare's drug price negotiations.
The industry trade group, PhRMA, has already approached Congress earlier this year regarding this issue, known as international reference pricing. The first source expressed apprehension about the potential upheaval this policy could trigger in the healthcare market, beyond just pharmaceuticals.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/04/44935195/elizabeth-warren-says-if-trump-illegally-fires-fed-chair-powell-hell-crash-our-markets-cause-more-economic-p" target="_blank" rel="noreferrer noopener">Elizabeth Warren Says, &#8216;If Trump Illegally Fires Fed Chair Powell, He&#8217;ll Crash Our Markets, Cause More Economic Pain To American Families&#8217;</a>
Why It Matters: Under Biden&#8217;s Inflation Reduction Act, the U.S. began negotiating prices for its costliest drugs. However, the negotiated prices for the first 10 drugs remain over twice as high—and sometimes five times higher—than what drugmakers charge in other wealthy nations. During his first term, President Donald Trump&#8216;s attempt to implement an international reference pricing program was halted by a court ruling.
The current report by Reuters comes on the heels of President Trump&#8217;s executive order <a href="https://www.benzinga.com/government/regulations/25/04/44851905/trumps-new-order-targets-drug-pricing-transparency-and-medicare-cost-reduction">aimed </a>at lowering drug prices and reducing Medicare costs signed earlier this month. The order instructed the Secretary of Health and Human Services to seek guidance for the Medicare Drug Price Negotiation Program for the initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028. 
This potential move is perceived as a major threat to the pharmaceutical industry. Boston University's Rena Conti told Reuters that drugmakers might respond to international reference pricing by raising prices in reference countries, potentially justifying higher U.S. prices and increasing global revenue.
Invesco Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>) and iShares U.S. Pharmaceuticals ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) declined 8.6% and 7.5%, respectively over the past month.
Price Action: During the pre-market session on Wednesday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) gained 2.39%, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) climbed 1.16% and 1.07%, respectively. Meanwhile, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) edged 0.48% higher.
<ul>
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/04/44930938/dogecoin-jumps-7-shiba-inu-up-4-is-a-major-meme-rally-brewing" target="_blank" rel="noreferrer noopener">Dogecoin Jumps 7%, Shiba Inu Up 4%: Is A Major Meme Rally Brewing? &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

News

Markets

iShares Dow Jones US Pharmaceuticals Index Fund

Trump Administration Considers Lowering US Drug Prices To International Levels: Report

Citigroup analyst Jon Tower downgrades Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) from Buy to Neutral and lowers the price target from $213 to $164.

Downgrades

Price Target

Analyst Ratings

TXRH

Citigroup Downgrades Texas Roadhouse to Neutral, Lowers Price Target to $164

Redburn Atlantic analyst Peter Low downgrades Chevron (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) from Neutral to Sell and lowers the price target from $156 to $124.

Redburn Atlantic Downgrades Chevron to Sell, Lowers Price Target to $124

<ul>
<li>The results of the in vitro release testing (IVRT) confirm that Ketamir-2 can be delivered reliably and consistently through a topical cream—a challenge that many water-soluble compounds fail to overcome when formulated in hydrophobic bases. This breakthrough provides MIRA with a new opportunity to pursue localized, non-opioid pain treatment options that may complement its oral Ketamir-2 formulation currently in Phase 1 trials.</li>
<li>MIRA is now initiating preclinical efficacy studies to assess whether the topical formulation can offer therapeutic effects in models of inflammatory and neuropathic pain. These studies are expected to provide data to guide potential clinical advancement.</li>
<li>MIRA is also evaluating whether the topical Ketamir-2 program may meet the criteria for Fast Track designation under the United States Food and Drug Administration ("FDA")'s expedited development program for serious conditions. If granted, Fast Track status could facilitate closer communication with the FDA and potentially accelerate the path to first-in-human studies.</li>
<li>MIRA's oral Ketamir-2 formulation is currently being evaluated in a Phase 1 clinical trial, with a Phase 2a trial in diabetic neuropathy expected to commence later this year.</li>
</ul>
&nbsp;

Biotech

Health Care

General

MIRA

MIRA Pharmaceuticals Announced A Key Development Milestone For Its Novel Topical Formulation Of Ketamir-2 Demonstrated Successful, Dose-proportional Drug Release In A Validated Laboratory Study-8K

PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>, BCTXW))) (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BCT#TSX">BCT</a>) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.
The details of the poster presentation sessions and publish-only abstract are listed below.
Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician's choice in advanced metastatic breast cancer (BRIA-ABC) Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: TPS1138 Poster Board Number: 108a Session Type and Title: Poster Session – Breast Cancer—Metastatic
Abstract Title: Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT Abstract Number for Publication: 1096 Poster Board Number: 75 Session Type and Title: Poster Session – Breast Cancer—Metastatic
Abstract Title: Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer Session Date and Time: 6/2/2025 9:00 AM-12:00 PM&nbsp;CDT Abstract Number for Publication: TPS1136 Poster Board Number: 107a Session Type and Title: Poster Session – Breast Cancer—Metastatic
Publish-Only Abstract Title: Impact of HLA Matching on Clinical Outcomes in a Phase 2 Trial of Bria-IMT&#x2122; Plus Anti PD1 in Advanced Breast Cancer
Abstracts will be released at 5:00 PM (ET) on Thursday, May 22, 2025.

BCTX

TSX:BCT

Briacell Therapeutics Announces Three Clinical Data Poster Presentations And One Publish-Only Abstract At 2025 ASCO Annual Meeting At McCormick Place, Chicago

WIIM

PROG Holdings shares are trading lower after the company reported Q1 financial results and lowered FY25 revenue and EPS outlook. It also issued weaker-than-expected Q2 outlook.

SAP shares are trading higher after the company reported better-than-expected Q1 financial results.

Earnings

Earnings Beats

NextEra Energy Q1 Adj. EPS $0.99 Beats $0.97 Estimate

Stock Yards Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYBT#NASDAQ">SYBT</a>) reported quarterly earnings of $1.13 per share which beat the analyst consensus estimate of $0.99 by 14.14 percent. This is a 28.41 percent increase over earnings of $0.88 per share from the same period last year. The company reported quarterly sales of $93.55 million which beat the analyst consensus estimate of $92.84 million by 0.76 percent. This is a 12.25 percent increase over sales of $83.34 million the same period last year.

SYBT

Stock Yards Bancorp Q1 EPS $1.13 Beats $0.99 Estimate, Sales $93.55M Beat $92.84M Estimate

2025 Outlook
In light of the deterioration in the macroeconomic environment since the Company issued its full-year outlook on February 19, 2025, the Company is updating its full year 2025 outlook for revenue and earnings as well as providing guidance for the second quarter of 2025. The updated outlook below assumes a difficult operating environment with soft demand for consumer durable goods, no material changes in the Company's current decisioning posture, an effective tax rate for Non-GAAP EPS of approximately 28%, and no impact from additional share repurchases. Additionally, the company has not assumed a recession which, among other factors, would likely be accompanied by a rise in the unemployment rate.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="6" rowspan="1">Revised 2025 Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="6" rowspan="1">Previous 2025 Outlook</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(In thousands, except per share amounts)</td>
<td colspan="3" rowspan="1">Low</td>
<td colspan="3" rowspan="1">High</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">Low</td>
<td colspan="3" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Total Revenues</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,425,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,500,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,515,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2,590,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Net Earnings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">109,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">125,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">115,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">133,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">245,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">265,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">260,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">280,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.62</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.01</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.82</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.22</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted Non-GAAP EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2.90</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.30</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.10</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">3.50</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Progressive Leasing - Total Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,300,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,360,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,385,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,445,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Progressive Leasing - Earnings Before Taxes</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">168,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">185,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">181,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">195,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Progressive Leasing - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">245,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">261,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">260,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">275,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vive - Total Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">60,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">70,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vive - Loss Before Taxes</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(5,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(3,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(5,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(2,500</td>
<td colspan="1" rowspan="1">)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Vive - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(2,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(1,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(2,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">—</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
<td colspan="3" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other - Total Revenues</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">75,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">65,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">75,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other - Loss Before Taxes</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(9,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(7,500</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(9,000</td>
<td colspan="1" rowspan="1">)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(6,000</td>
<td colspan="1" rowspan="1">)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,500</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="4" rowspan="1">
Three Months Ended
June 30, 2025 Outlook
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(In thousands, except per share amounts)</td>
<td colspan="2" rowspan="1">Low</td>
<td colspan="2" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Total Revenues</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">575,000</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">595,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Net Earnings</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">28,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">32,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">61,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">66,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.68</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.77</td>
</tr>
<tr>
<td colspan="1" rowspan="1">PROG Holdings - Diluted Non-GAAP EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.75</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.85</td>
</tr>
</tbody>
</table>
</figure>

Guidance

PROG Holdings Q2 GAAP EPS Outlook $0.68-$0.77 Vs $0.84 Estimate

San Diego, California--(Newsfile Corp. - April 23, 2025) - Sonim Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>), a leading U.S. provider of rugged mobile solutions, today announced significant progress in the execution of its expansion strategy, underscoring the company's commitment to long term growth and operational excellence. The foundation laid through strategic investments in 2024 has positioned Sonim for success through the development and delivery of new products and product categories, new customer acquisitions, the retention of an existing customer base due to upgrades to the next generation portfolio, and market expansion across North America, Europe, South Africa, and Australia.
New products set to launch in North America, EMEA, and Australia
Sonim is set to launch three products as stocked offerings in the second quarter with Tier 1 carriers in North America. These include the company's flagship Sonim XP Pro next generation rugged 5G smartphone.
Three additional products are slated to launch in the second quarter with leading distribution partners and Tier 1 operators, including Deutsche Telekom in Germany, which currently stocks three Sonim SKUs. These new placements further strengthen Sonim's growing footprint in these key markets.
Purchase orders for second quarter launches
Validating market demand, purchase orders have already been placed for Sonim's upcoming product launches late in the second quarter. &nbsp;

SONM

Sonim Technologies Accelerates Expansion Strategy With Strong Momentum In Q2 2025; New Products Set To Launch In North America, EMEA, And Australia

PONY

Pony.ai Debuts 7th-Gen Autonomous System, Showcases Robotaxi Fleet At Shanghai Auto Show

PROG Holdings Q2 Outlook: Adj EPS $0.75-$0.85 Vs $0.90 Estimate; Sales $575.000M-$595.000M Vs $616.41M Estimate

JMP Securities analyst Silvan Tuerkcan initiates coverage on Foghorn Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FHTX#NASDAQ">FHTX</a>) with a Market Outperform rating and announces Price Target of $9.

Initiation

FHTX

JMP Securities Initiates Coverage On Foghorn Therapeutics with Market Outperform Rating, Announces Price Target of $9

PROG Holdings Lowers FY25 GAAP EPS Guidance From $2.82-$3.22 To $2.62-$3.01 Vs $3.12 Estimate

ROLLE, Switzerland and PLYMOUTH, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>), a leading differentiated automotive technology provider and Shaanxi Hande Axle Co., Ltd. (HanDe), a leading Chinese axle manufacturer for commercial vehicles, have signed a strategic agreement, including a series production award, to co-develop and manufacture advanced electric beam axle systems for medium and heavy-duty trucks. The signing took place today at the Shanghai Auto Show—China's flagship platform for mobility innovation—marking a significant milestone in the electrification of commercial transport.
Under the agreement, Garrett and HanDe will co-develop next-generation electric beam axle systems across truck weight classes, with production targeted for 2027. The solution will integrate Garrett's high-speed e-motor and inverter technology into HanDe's proven axle and transmission platforms—delivering industry-leading TCO, high performance, efficient packaging, and system scalability.
The strategic partnership includes a multi-year production award from major Chinese commercial vehicle manufacturers and will support both high-volume domestic output and international expansion. Initial manufacturing will take place in Xi'an and Wuhan, with test fleets set to begin field trials in 2026 as part of a broader global rollout strategy.
 &nbsp;

Garrett Motion Signs Strategic Agreement With Shaanxi Hande Axle To Co-Develop And Manufacture Advanced Electric Beam Axle Systems For Medium And Heavy-Duty Trucks

PROG Holdings Lowers FY25 Outlook: Adj EPS From $3.10-$3.50 To $2.90-$3.30 Vs $3.34 Estimate; Sales From $2.52B-$2.59B To $2.42B-$2.50B Vs $2.55B Estimate

Watsco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSO#NYSE">WSO</a>) reported quarterly earnings of $1.93 per share which missed the analyst consensus estimate of $2.25 by 14.22 percent. This is a 11.06 percent decrease over earnings of $2.17 per share from the same period last year. The company reported quarterly sales of $1.53 billion which missed the analyst consensus estimate of $1.65 billion by 7.46 percent. This is a 2.17 percent decrease over sales of $1.56 billion the same period last year.

Earnings Misses

Watsco Q1 EPS $1.93 Misses $2.25 Estimate, Sales $1.53B Miss $1.65B Estimate

JMP Securities analyst Silvan Tuerkcan initiates coverage on Nuvation Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUVB#NYSE">NUVB</a>) with a Market Outperform rating and announces Price Target of $6.

NUVB

JMP Securities Initiates Coverage On Nuvation Bio with Market Outperform Rating, Announces Price Target of $6

Boeing shares are trading higher after the company reported better-than-expected Q1 financial results.

Press Releases

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Comments

Immatics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL